Literature DB >> 1378865

CD40 is functionally expressed on human thymic epithelial cells.

A H Galy1, H Spits.   

Abstract

CD40 is a prominent B cell Ag also found on certain epithelial cells and on carcinomas. In this report, we analyzed CD40 distribution in the human thymus. CD40 was not found on the majority of CD45-positive thymocytes, but was present in a CD45-negative stromal cell population. Immunohistology showed CD40 expression on cortical thymic epithelial cells (TEC), medullary TEC, thymic interdigitating cells, and thymic B cells. CD40 was not found on thymocytes, endothelial cells, or on the fibroblasts of the septae. Expression of CD40 was specifically maintained on cultured TEC and not found on cultured thymic fibroblasts. IL-1 alpha, TNF-alpha, IFN-gamma, but not IL-4, significantly up-regulated the membrane expression of CD40 on cultured TEC. The regulation of CD40 was similar to that of ICAM-1, and contrasted with that of MHC class II Ag, which could only be induced by IFN-gamma but not by IL-1, TNF, or IL-4. Northern blot analysis showed the presence of a 1.4-kb mRNA transcript for CD40 in TEC, which was up-regulated by IL-1 and IFN-gamma. Cross-linking of CD40 at the surface of human TEC in the absence of IL-1 stimulation failed to induce cytokine secretion. Triggering of TEC with anti-CD40 mAb in conjunction with IFN-gamma and IL-1 stimulation increased granulocyte-macrophage CSF secretion in a dose-dependent manner. The effect was visible as early as 24 h after triggering, occurred in the absence of cellular proliferation, and was specific for CD40 since triggering of other TEC membrane Ag such as ICAM-1 or MHC class I molecules had no effect to increase cytokine production in TEC. These data demonstrate that CD40 is expressed and is a functional molecule at the surface of the epithelial cells of the thymus.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378865

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

Review 1.  Therapeutic potential for blockade of the CD40 ligand, gp39.

Authors:  J E Buhlmann; R J Noelle
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

2.  A functional CD40 receptor is expressed in pancreatic beta cells.

Authors:  D Klein; F Barbé-Tuana; A Pugliese; H Ichii; D Garza; M Gonzalez; R D Molano; C Ricordi; R L Pastori
Journal:  Diabetologia       Date:  2005-02-03       Impact factor: 10.122

3.  The role of hepatocyte growth factor and its receptor c-met in interactions between lymphocytes and stromal cells in secondary human lymphoid organs.

Authors:  G Skibinski; A Skibinska; K James
Journal:  Immunology       Date:  2001-04       Impact factor: 7.397

4.  Foxp3+ regulatory T cells promiscuously accept thymic signals critical for their development.

Authors:  Philip J Spence; E Allison Green
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-15       Impact factor: 11.205

Review 5.  The molecular basis for T cell help in humoral immunity: CD40 and its ligand, gp39.

Authors:  L S Marshall; A Aruffo; J A Ledbetter; R J Noelle
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

Review 6.  The biology of the human ligand for CD40.

Authors:  M K Spriggs; W C Fanslow; R J Armitage; J Belmont
Journal:  J Clin Immunol       Date:  1993-11       Impact factor: 8.317

Review 7.  The hyper-IgM (HIM) syndrome.

Authors:  N Ramesh; M Seki; L D Notarangelo; R S Geha
Journal:  Springer Semin Immunopathol       Date:  1998

8.  Influence of the lpr environment on the lymph node cell phenotypes in C57BL/6 nubg and nulpr chimeras.

Authors:  F Tiberghien; R Ceredig; F Loor
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

9.  T cell clones from an X-linked hyper-immunoglobulin (IgM) patient induce IgE synthesis in vitro despite expression of nonfunctional CD40 ligand.

Authors:  P Life; J F Gauchat; V Schnuriger; S Estoppey; G Mazzei; A Durandy; A Fischer; J Y Bonnefoy
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

10.  CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.

Authors:  Eric D Hsi; Roxanne Steinle; Balaji Balasa; Susann Szmania; Aparna Draksharapu; Benny P Shum; Mahrukh Huseni; David Powers; Amulya Nanisetti; Yin Zhang; Audie G Rice; Anne van Abbema; Melanie Wong; Gao Liu; Fenghuang Zhan; Myles Dillon; Shihao Chen; Susan Rhodes; Franklin Fuh; Naoya Tsurushita; Shankar Kumar; Vladimir Vexler; John D Shaughnessy; Bart Barlogie; Frits van Rhee; Mohamad Hussein; Daniel E H Afar; Marna B Williams
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.